

Butorphanol Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 06.07.2024
4.0	03.12.2024	918653-00020	Date of first issue: 03.10.2016

SECTION 1: IDENTIFICATION

Product name : Butorphanol Formulation

Other means of identification : Dolorex® (A006877)

Manufacturer or supplier's details

Company : Intervet Australia Pty Limited (trading as MSD Animal Health)

Address : 91-105 Harpin Street
Bendigo 3550, Victoria Australia

Telephone : 1 800 033 461

Emergency telephone number : Poisons Information Centre: Phone 13 11 26

E-mail address : EHSDATASTEWARD@msd.com

Recommended use of the chemical and restrictions on use

Recommended use : Veterinary product

Restrictions on use : Not applicable

SECTION 2. HAZARDS IDENTIFICATION**GHS Classification**

Specific target organ toxicity - single exposure (Oral) : Category 2 (Central nervous system)

Specific target organ toxicity - repeated exposure (Oral) : Category 2 (Blood, Central nervous system)

GHS label elements

Hazard pictograms :



Signal word : Warning

Hazard statements : H371 May cause damage to organs (Central nervous system) if swallowed.
H373 May cause damage to organs (Blood, Central nervous system) through prolonged or repeated exposure if swallowed.

Precautionary statements : **Prevention:**
P260 Do not breathe mist or vapours.
P264 Wash skin thoroughly after handling.

Butorphanol Formulation

Version 4.0	Revision Date: 03.12.2024	SDS Number: 918653-00020	Date of last issue: 06.07.2024 Date of first issue: 03.10.2016
----------------	------------------------------	-----------------------------	---

P270 Do not eat, drink or smoke when using this product.

Response:

P308 + P311 IF exposed or concerned: Call a POISON CENTER/ doctor.

Storage:

P405 Store locked up.

Disposal:

P501 Dispose of contents/ container to an approved waste disposal plant.

Other hazards which do not result in classification

None known.

SECTION 3. COMPOSITION/INFORMATION ON INGREDIENTS

Substance / Mixture : Mixture

Components

Chemical name	CAS-No.	Concentration (% w/w)
17-(cyclobutylmethyl)morphinan-3,14-diyl [S-(R*,R*)]-2,3-dihydroxysuccinate	58786-99-5	>= 1 -< 3

SECTION 4. FIRST AID MEASURES

General advice	: In the case of accident or if you feel unwell, seek medical advice immediately. When symptoms persist or in all cases of doubt seek medical advice.
If inhaled	: If inhaled, remove to fresh air. Get medical attention.
In case of skin contact	: In case of contact, immediately flush skin with soap and plenty of water. Remove contaminated clothing and shoes. Get medical attention. Wash clothing before reuse. Thoroughly clean shoes before reuse.
In case of eye contact	: Flush eyes with water as a precaution. Get medical attention if irritation develops and persists.
If swallowed	: If swallowed, DO NOT induce vomiting. Get medical attention. Rinse mouth thoroughly with water. Never give anything by mouth to an unconscious person.
Most important symptoms and effects, both acute and delayed	: May cause damage to organs if swallowed. May cause damage to organs through prolonged or repeated exposure if swallowed.
Protection of first-aiders	: First Aid responders should pay attention to self-protection, and use the recommended personal protective equipment when the potential for exposure exists (see section 8).
Notes to physician	: Treat symptomatically and supportively.

Butorphanol Formulation

Version 4.0	Revision Date: 03.12.2024	SDS Number: 918653-00020	Date of last issue: 06.07.2024 Date of first issue: 03.10.2016
----------------	------------------------------	-----------------------------	---

SECTION 5. FIREFIGHTING MEASURES

- Suitable extinguishing media : Water spray
Alcohol-resistant foam
Carbon dioxide (CO₂)
Dry chemical
- Unsuitable extinguishing media : None known.
- Specific hazards during fire-fighting : Exposure to combustion products may be a hazard to health.
- Hazardous combustion products : Carbon oxides
- Specific extinguishing methods : Use extinguishing measures that are appropriate to local circumstances and the surrounding environment.
Use water spray to cool unopened containers.
Remove undamaged containers from fire area if it is safe to do so.
Evacuate area.
- Special protective equipment for firefighters : In the event of fire, wear self-contained breathing apparatus.
Use personal protective equipment.

SECTION 6. ACCIDENTAL RELEASE MEASURES

- Personal precautions, protective equipment and emergency procedures : Use personal protective equipment.
Follow safe handling advice (see section 7) and personal protective equipment recommendations (see section 8).
- Environmental precautions : Avoid release to the environment.
Prevent further leakage or spillage if safe to do so.
Prevent spreading over a wide area (e.g. by containment or oil barriers).
Retain and dispose of contaminated wash water.
Local authorities should be advised if significant spillages cannot be contained.
- Methods and materials for containment and cleaning up : Soak up with inert absorbent material.
For large spills, provide dyking or other appropriate containment to keep material from spreading. If dyked material can be pumped, store recovered material in appropriate container.
Clean up remaining materials from spill with suitable absorbent.
Local or national regulations may apply to releases and disposal of this material, as well as those materials and items employed in the cleanup of releases. You will need to determine which regulations are applicable.

Butorphanol Formulation

Version	Revision Date:	SDS Number:	Date of last issue:
4.0	03.12.2024	918653-00020	06.07.2024
			Date of first issue: 03.10.2016

Sections 13 and 15 of this SDS provide information regarding certain local or national requirements.

SECTION 7. HANDLING AND STORAGE

- Technical measures : See Engineering measures under EXPOSURE CONTROLS/PERSONAL PROTECTION section.
- Local/Total ventilation : Use only with adequate ventilation.
- Advice on safe handling : Do not breathe mist or vapours.
Do not swallow.
Avoid contact with eyes.
Avoid prolonged or repeated contact with skin.
Wash skin thoroughly after handling.
Handle in accordance with good industrial hygiene and safety practice, based on the results of the workplace exposure assessment
Do not eat, drink or smoke when using this product.
Take care to prevent spills, waste and minimize release to the environment.
- Hygiene measures : If exposure to chemical is likely during typical use, provide eye flushing systems and safety showers close to the working place.
When using do not eat, drink or smoke.
Wash contaminated clothing before re-use.
The effective operation of a facility should include review of engineering controls, proper personal protective equipment, appropriate degowning and decontamination procedures, industrial hygiene monitoring, medical surveillance and the use of administrative controls.
- Conditions for safe storage : Keep in properly labelled containers.
Store locked up.
Store in accordance with the particular national regulations.
- Materials to avoid : Do not store with the following product types:
Strong oxidizing agents

SECTION 8. EXPOSURE CONTROLS/PERSONAL PROTECTION

Components with workplace control parameters

Components	CAS-No.	Value type (Form of exposure)	Control parameters / Permissible concentration	Basis
17-(cyclobutylmethyl)morphinan-3,14-diyl [S-(R*,R*)]-2,3-dihydroxysuccinate	58786-99-5	TWA	3 µg/m ³ (OEB 4)	Internal
		Wipe limit	30 µg/100 cm ²	Internal
		STEL	25 µg/m ³	Internal

- Engineering measures : The information below is intended for larger pilot/commercial-

Butorphanol Formulation

Version	Revision Date:	SDS Number:	Date of last issue:
4.0	03.12.2024	918653-00020	06.07.2024
			Date of first issue: 03.10.2016

scale operations and manufacturing. For smaller scale, clinical, or pharmacy settings, site-specific internal risk assessment practices should be conducted to determine appropriate exposure control measures. The health hazard risks of handling this material are dependent on multiple factors, including but not limited to physical form and quantity handled. If applicable, use process enclosures, local exhaust ventilation (e.g., Biosafety Cabinet, Ventilated Balance Enclosures), or other engineering controls to maintain airborne levels below recommended exposure limits. If exposure limits have not been established, maintain airborne levels as low as reasonably achievable.

All engineering controls should be implemented by facility design and operated in accordance with GMP principles to protect products, workers, and the environment.

Essentially no open handling permitted.

Use closed processing systems or containment technologies. If handled in a laboratory, use a properly designed biosafety cabinet, fume hood, or other containment device if the potential exists for aerosolization. If this potential does not exist, handle over lined trays or benchtops.

Personal protective equipment

- | | | |
|--------------------------|---|--|
| Respiratory protection | : | If adequate local exhaust ventilation is not available or exposure assessment demonstrates exposures outside the recommended guidelines, use respiratory protection. |
| Filter type | : | Particulates type |
| Hand protection | : | |
| Material | : | Chemical-resistant gloves |
| Remarks | : | Consider double gloving. |
| Eye protection | : | Wear safety glasses with side shields or goggles. If the work environment or activity involves dusty conditions, mists or aerosols, wear the appropriate goggles. Wear a faceshield or other full face protection if there is a potential for direct contact to the face with dusts, mists, or aerosols. |
| Skin and body protection | : | Work uniform or laboratory coat. Additional body garments should be used based upon the task being performed (e.g., sleevelets, apron, gauntlets, disposable suits) to avoid exposed skin surfaces. Use appropriate degowning techniques to remove potentially contaminated clothing. |

SECTION 9. PHYSICAL AND CHEMICAL PROPERTIES

- | | | |
|------------|---|-------------------|
| Appearance | : | liquid |
| Colour | : | colourless |
| Odour | : | No data available |

Butorphanol Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 06.07.2024
4.0	03.12.2024	918653-00020	Date of first issue: 03.10.2016

Odour Threshold	:	No data available
pH	:	No data available
Melting point/freezing point	:	No data available
Initial boiling point and boiling range	:	100 °C
Flash point	:	No data available
Evaporation rate	:	No data available
Flammability (solid, gas)	:	Not applicable
Flammability (liquids)	:	No data available
Upper explosion limit / Upper flammability limit	:	No data available
Lower explosion limit / Lower flammability limit	:	No data available
Vapour pressure	:	No data available
Relative vapour density	:	No data available
Relative density	:	No data available
Density	:	No data available
Solubility(ies) Water solubility	:	No data available
Partition coefficient: n-octanol/water	:	Not applicable
Auto-ignition temperature	:	No data available
Decomposition temperature	:	No data available
Viscosity Viscosity, kinematic	:	No data available
Explosive properties	:	Not explosive
Oxidizing properties	:	The substance or mixture is not classified as oxidizing.
Particle characteristics Particle size	:	Not applicable

Butorphanol Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 06.07.2024
4.0	03.12.2024	918653-00020	Date of first issue: 03.10.2016

SECTION 10. STABILITY AND REACTIVITY

Reactivity	: Not classified as a reactivity hazard.
Chemical stability	: Stable under normal conditions.
Possibility of hazardous reactions	: Can react with strong oxidizing agents.
Conditions to avoid	: None known.
Incompatible materials	: Oxidizing agents
Hazardous decomposition products	: No hazardous decomposition products are known.

SECTION 11. TOXICOLOGICAL INFORMATION

Exposure routes	: Inhalation Skin contact Ingestion Eye contact
-----------------	--

Acute toxicity

Not classified based on available information.

Product:

Acute oral toxicity	: Acute toxicity estimate: > 2,000 mg/kg Method: Calculation method
---------------------	--

Components:**17-(cyclobutylmethyl)morphinan-3,14-diyl [S-(R*,R*)]-2,3-dihydroxysuccinate:**

Acute oral toxicity	: LD50 (Mouse): 395 mg/kg LD50 (Dog): > 50 mg/kg LD50 (Monkey): > 50 mg/kg
Acute inhalation toxicity	: Remarks: No data available
Acute dermal toxicity	: Remarks: No data available

Skin corrosion/irritation

Not classified based on available information.

Components:**17-(cyclobutylmethyl)morphinan-3,14-diyl [S-(R*,R*)]-2,3-dihydroxysuccinate:**

Remarks	: No data available
---------	---------------------

Serious eye damage/eye irritation

Not classified based on available information.

Butorphanol Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 06.07.2024
4.0	03.12.2024	918653-00020	Date of first issue: 03.10.2016

Components:**17-(cyclobutylmethyl)morphinan-3,14-diyl [S-(R*,R*)]-2,3-dihydroxysuccinate:**

Species	: Rat
Result	: No eye irritation

Respiratory or skin sensitisation**Skin sensitisation**

Not classified based on available information.

Respiratory sensitisation

Not classified based on available information.

Components:**17-(cyclobutylmethyl)morphinan-3,14-diyl [S-(R*,R*)]-2,3-dihydroxysuccinate:**

Exposure routes	: Dermal
Assessment	: Does not cause skin sensitisation.
Result	: negative

Chronic toxicity**Germ cell mutagenicity**

Not classified based on available information.

Components:**17-(cyclobutylmethyl)morphinan-3,14-diyl [S-(R*,R*)]-2,3-dihydroxysuccinate:**

Genotoxicity in vitro	: Test Type: Bacterial reverse mutation assay (AMES) Result: negative
	Test Type: DNA damage and repair, unscheduled DNA synthesis in mammalian cells (in vitro) Result: negative

Carcinogenicity

Not classified based on available information.

Components:**17-(cyclobutylmethyl)morphinan-3,14-diyl [S-(R*,R*)]-2,3-dihydroxysuccinate:**

Species	: Rat
Application Route	: Oral
Exposure time	: 2 Years
Result	: negative

Species	: Mouse
Application Route	: Oral
Exposure time	: 2 Years
Result	: negative

Butorphanol Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 06.07.2024
4.0	03.12.2024	918653-00020	Date of first issue: 03.10.2016

Reproductive toxicity

Not classified based on available information.

Components:**17-(cyclobutylmethyl)morphinan-3,14-diyl [S-(R*,R*)]-2,3-dihydroxysuccinate:**

Effects on fertility	:	Test Type: Fertility/early embryonic development Species: Rat Application Route: Oral Fertility: LOAEL: 160 mg/kg body weight Result: Effects on fertility
Effects on foetal development	:	Test Type: Embryo-foetal development Species: Rat Application Route: Subcutaneous Developmental Toxicity: LOAEL: 1 mg/kg body weight Result: No teratogenic effects, Increased stillbirths
		Test Type: Embryo-foetal development Species: Rabbit Application Route: Oral Developmental Toxicity: LOAEL: 30 mg/kg body weight Result: No teratogenic effects, Maternal toxicity observed., Postimplantation loss.
		Test Type: Embryo-foetal development Species: Rat Application Route: Subcutaneous Developmental Toxicity: LOAEL: 0.5 mg/kg body weight Result: Maternal toxicity observed.
Reproductive toxicity - Assessment	:	Some evidence of adverse effects on sexual function and fertility, based on animal experiments., Some evidence of adverse effects on development, based on animal experiments.

STOT - single exposure

May cause damage to organs (Central nervous system) if swallowed.

Components:**17-(cyclobutylmethyl)morphinan-3,14-diyl [S-(R*,R*)]-2,3-dihydroxysuccinate:**

Target Organs	:	Central nervous system
Assessment	:	Causes damage to organs.

STOT - repeated exposure

May cause damage to organs (Blood, Central nervous system) through prolonged or repeated exposure if swallowed.

Butorphanol Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 06.07.2024
4.0	03.12.2024	918653-00020	Date of first issue: 03.10.2016

Components:**17-(cyclobutylmethyl)morphinan-3,14-diyl [S-(R*,R*)]-2,3-dihydroxysuccinate:**

Target Organs	: Blood, Central nervous system
Assessment	: Causes damage to organs through prolonged or repeated exposure.

Repeated dose toxicity**Components:****17-(cyclobutylmethyl)morphinan-3,14-diyl [S-(R*,R*)]-2,3-dihydroxysuccinate:**

Species	: Rat
LOAEL	: 0.4 mg/kg
Application Route	: Subcutaneous
Exposure time	: 6 Months
Target Organs	: Blood, Central nervous system

Species	: Monkey
LOAEL	: 0.15 mg/kg
Application Route	: Intramuscular
Exposure time	: 6 Months
Target Organs	: Central nervous system

Species	: Dog
LOAEL	: 0.1 mg/kg
Application Route	: Intramuscular
Exposure time	: 3 Months
Symptoms	: reduced body weight gain

Aspiration toxicity

Not classified based on available information.

Experience with human exposure**Components:****17-(cyclobutylmethyl)morphinan-3,14-diyl [S-(R*,R*)]-2,3-dihydroxysuccinate:**

Ingestion	: Symptoms: Drowsiness, Sweating, Nausea, Dizziness, Vertigo, Palpitation, respiratory depression
-----------	---

SECTION 12. ECOLOGICAL INFORMATION**Ecotoxicity****Components:****17-(cyclobutylmethyl)morphinan-3,14-diyl [S-(R*,R*)]-2,3-dihydroxysuccinate:**

Toxicity to daphnia and other aquatic invertebrates	: EC50 (Daphnia magna (Water flea)): 38.1 mg/l Exposure time: 48 h Method: OECD Test Guideline 202
---	--

Butorphanol Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 06.07.2024
4.0	03.12.2024	918653-00020	Date of first issue: 03.10.2016

Persistence and degradability

No data available

Bioaccumulative potential

No data available

Mobility in soil

No data available

Other adverse effects

No data available

SECTION 13. DISPOSAL CONSIDERATIONS**Disposal methods**

Waste from residues	:	Do not dispose of waste into sewer. Dispose of in accordance with local regulations.
Contaminated packaging	:	Empty containers should be taken to an approved waste handling site for recycling or disposal. If not otherwise specified: Dispose of as unused product.

SECTION 14. TRANSPORT INFORMATION**International Regulations****UNRTDG**

UN number	:	Not applicable
Proper shipping name	:	Not applicable
Class	:	Not applicable
Subsidiary risk	:	Not applicable
Packing group	:	Not applicable
Labels	:	Not applicable
Environmentally hazardous	:	no

IATA-DGR

UN/ID No.	:	Not applicable
Proper shipping name	:	Not applicable
Class	:	Not applicable
Subsidiary risk	:	Not applicable
Packing group	:	Not applicable
Labels	:	Not applicable
Packing instruction (cargo aircraft)	:	Not applicable
Packing instruction (passenger aircraft)	:	Not applicable

IMDG-Code

UN number	:	Not applicable
Proper shipping name	:	Not applicable
Class	:	Not applicable
Subsidiary risk	:	Not applicable
Packing group	:	Not applicable
Labels	:	Not applicable

Butorphanol Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 06.07.2024
4.0	03.12.2024	918653-00020	Date of first issue: 03.10.2016

EmS Code : Not applicable
Marine pollutant : Not applicable

Transport in bulk according to Annex II of MARPOL 73/78 and the IBC Code

Not applicable for product as supplied.

National Regulations**ADG**

UN number : Not applicable
Proper shipping name : Not applicable
Class : Not applicable
Subsidiary risk : Not applicable
Packing group : Not applicable
Labels : Not applicable
Hazchem Code : Not applicable

Special precautions for user

Not applicable

SECTION 15. REGULATORY INFORMATION**Safety, health and environmental regulations/legislation specific for the substance or mixture**

Therapeutic Goods (Poisons Standard) Instrument : No poison schedule number allocated (Please use the original publication to check for specific uses, specific conditions or threshold limits that might apply for this chemical)

Prohibition/Licensing Requirements : There is no applicable prohibition, authorisation and restricted use requirements, including for carcinogens referred to in Schedule 10 of the model WHS Act and Regulations.

The components of this product are reported in the following inventories:

AICS : not determined
DSL : not determined
IECSC : not determined

SECTION 16: ANY OTHER RELEVANT INFORMATION**Further information**

Revision Date : 03.12.2024
Sources of key data used to compile the Safety Data Sheet : Internal technical data, data from raw material SDSs, OECD eChem Portal search results and European Chemicals Agency, <http://echa.europa.eu/>

Items where changes have been made to the previous version are highlighted in the body of this document by two vertical lines.

Butorphanol Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 06.07.2024
4.0	03.12.2024	918653-00020	Date of first issue: 03.10.2016

Date format : dd.mm.yyyy

Full text of other abbreviations

AIIC - Australian Inventory of Industrial Chemicals; ANTT - National Agency for Transport by Land of Brazil; ASTM - American Society for the Testing of Materials; bw - Body weight; CMR - Carcinogen, Mutagen or Reproductive Toxicant; DIN - Standard of the German Institute for Standardisation; DSL - Domestic Substances List (Canada); ECx - Concentration associated with x% response; ELx - Loading rate associated with x% response; EmS - Emergency Schedule; ENCS - Existing and New Chemical Substances (Japan); ErCx - Concentration associated with x% growth rate response; ERG - Emergency Response Guide; GHS - Globally Harmonized System; GLP - Good Laboratory Practice; IARC - International Agency for Research on Cancer; IATA - International Air Transport Association; IBC - International Code for the Construction and Equipment of Ships carrying Dangerous Chemicals in Bulk; IC50 - Half maximal inhibitory concentration; ICAO - International Civil Aviation Organization; IECSC - Inventory of Existing Chemical Substances in China; IMDG - International Maritime Dangerous Goods; IMO - International Maritime Organization; ISHL - Industrial Safety and Health Law (Japan); ISO - International Organisation for Standardization; KECI - Korea Existing Chemicals Inventory; LC50 - Lethal Concentration to 50 % of a test population; LD50 - Lethal Dose to 50% of a test population (Median Lethal Dose); MARPOL - International Convention for the Prevention of Pollution from Ships; n.o.s. - Not Otherwise Specified; Nch - Chilean Norm; NO(A)EC - No Observed (Adverse) Effect Concentration; NO(A)EL - No Observed (Adverse) Effect Level; NOELR - No Observable Effect Loading Rate; NOM - Official Mexican Norm; NTP - National Toxicology Program; NZIoC - New Zealand Inventory of Chemicals; OECD - Organization for Economic Co-operation and Development; OPPTS - Office of Chemical Safety and Pollution Prevention; PBT - Persistent, Bioaccumulative and Toxic substance; PICCS - Philippines Inventory of Chemicals and Chemical Substances; (Q)SAR - (Quantitative) Structure Activity Relationship; REACH - Regulation (EC) No 1907/2006 of the European Parliament and of the Council concerning the Registration, Evaluation, Authorisation and Restriction of Chemicals; SADT - Self-Accelerating Decomposition Temperature; SDS - Safety Data Sheet; TCSI - Taiwan Chemical Substance Inventory; TDG - Transportation of Dangerous Goods; TECI - Thailand Existing Chemicals Inventory; TSCA - Toxic Substances Control Act (United States); UN - United Nations; UNRTDG - United Nations Recommendations on the Transport of Dangerous Goods; vPvB - Very Persistent and Very Bioaccumulative; WHMIS - Workplace Hazardous Materials Information System

The information provided in this Safety Data Sheet is correct to the best of our knowledge, information and belief at the date of its publication. The information is designed only as a guidance for safe handling, use, processing, storage, transportation, disposal and release and shall not be considered a warranty or quality specification of any type. The information provided relates only to the specific material identified at the top of this SDS and may not be valid when the SDS material is used in combination with any other materials or in any process, unless specified in the text. Material users should review the information and recommendations in the specific context of their intended manner of handling, use, processing and storage, including an assessment of the appropriateness of the SDS material in the user's end product, if applicable.

AU / EN